3-Propylamino-cis-crotonsaeure-ethylester | 28043-72-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-Propylamino-cis-crotonsaeure-ethylester
• 英文别名: ethyl (E)-3-(propylamino)but-2-enoate
• CAS: 28043-72-3
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: PAZDNVYVODMRHV-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Propylamino-cis-crotonsaeure-ethylester 在 sodium hydroxide 作用下， 以 various solvent(s) 为溶剂， 反应 3.0h， 生成 4-Hydroxy-2-methyl-6-oxo-5-phenyl-1-propyl-1,6-dihydro-pyridine-3-carboxylic acid
  参考文献：
  名称：

  Anti-mycobacterial 4-hydroxy-3-phenylpyridin-2 (1H)-ones

  摘要：

  4-Hydroxy-3-phenylpyridin-2 (1H)-ones with different substituents either at N-1 or in the phenyl group were synthesized by reaction of ethyl-beta-aminocrotonates with dialkyl malonates or 'magic malonates' (2,4,6-trichlorophenyl malonates). The evaluation of these compounds on Mycobacterium tuberculosis H37Ra, Escherichia coli B and Staphylococcus aureus ATCC 25923 showed significant inhibitory effects on M tuberculosis (5g and 5s, MIC = 8-mu-g/ml). A structure-activity relationship is discussed.

  DOI：

  10.1016/0223-5234(91)90194-r

文献信息

• Pyridone derivatives as NK3 antagonists
  申请人：Khanzhin Nikolay

  公开号：US20110144164A1

  公开（公告）日：2011-06-16

  The present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

  本发明涉及在治疗中有用的化合物，特别是在治疗精神病方面，涉及包含该化合物的组合物，以及包括给予该化合物的治疗方法。
• [EN] PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIDONE ANTAGONISTES DE NK3
  申请人：LUNDBECK & CO AS H

  公开号：WO2011072691A1

  公开（公告）日：2011-06-23

  The present invention relates to compound of formula (I) useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

  本发明涉及一种具有式（I）的化合物，用于治疗，特别是在治疗精神病方面，包括所述化合物的组合物，以及通过给予该化合物来治疗疾病的方法。
• Benzannulation and <i>N</i> ‐Annulation of β‐Ketoenamines for Synthesizing Aniline and Pyridine Derivatives Using DMSO as a Methine Source
  作者：Pallaba Ganjan Dalai、Niranjan Panda

  DOI：10.1002/adsc.202200886

  日期：2022.11.8

  N-annulation of β-ketoenamines by the in-situ generated methyl(methylene)sulfonium ion from the reaction of dimethyl sulfoxide (DMSO) and 1,2-dibromoethane (DBE) was achieved. The β-ketoenamines underwent N-annulation to pyridine derivatives, while the N-alkylated enamines were benzannulated to afford substituted anilines. The utility of the intermediate methyl(methylene)sulfonium ion was further extended for

  通过二甲基亚砜（DMSO）和1,2-二溴乙烷（DBE）的反应原位产生的甲基（亚甲基）锍离子实现了β-酮烯胺的苯环化和N-环化。β-酮烯胺经 N-环化生成吡啶衍生物，而N-烷基化烯胺经苯环化生成取代的苯胺。中间体甲基（亚甲基）锍离子的用途进一步扩展用于合成亚甲基桥联双-1,3-二羰基化合物。
• PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS
  申请人：H. Lundbeck A/S

  公开号：EP2513061A1

  公开（公告）日：2012-10-24
• US8207347B2
  申请人：——

  公开号：US8207347B2

  公开（公告）日：2012-06-26